eflornithine has been researched along with Anaplastic Oligodendroglioma in 2 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Excerpt | Relevance | Reference |
---|---|---|
"In the current study, we sought to determine whether the addition of DFMO (alpha-difluoromethyl ornithine; eflornithine), an inhibitor of ornithine decarboxylase, to a nitrosourea-based therapy procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, vincristine (PCV) would be more effective as a postirradiation adjuvant therapy for anaplastic gliomas (AG) than PCV alone." | 5.10 | Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. ( Bruner, JM; Choucair, A; Flynn, PJ; Gleason, MJ; Hess, KR; Ictech, S; Jaeckle, KA; Kim, HW; Kyritsis, AP; Levin, VA; Prados, MD; Yung, WK, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Levin, VA | 2 |
Hess, KR | 1 |
Choucair, A | 1 |
Flynn, PJ | 1 |
Jaeckle, KA | 1 |
Kyritsis, AP | 1 |
Yung, WK | 1 |
Prados, MD | 1 |
Bruner, JM | 1 |
Ictech, S | 1 |
Gleason, MJ | 1 |
Kim, HW | 1 |
Jochec, JL | 1 |
Shantz, LM | 1 |
Koch, PE | 1 |
Pegg, AE | 1 |
1 trial available for eflornithine and Anaplastic Oligodendroglioma
Article | Year |
---|---|
Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 2003 |
1 other study available for eflornithine and Anaplastic Oligodendroglioma
Article | Year |
---|---|
Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Eflornithine; Humans; Immunohistochemi | 2004 |